You are here
TESARO Announces Participation at Three Investor Conferences
WALTHAM, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor conferences. The three conferences are:
- Citi’s 13th Annual Biotech Day at the Four Seasons Hotel in Boston on Wednesday, September 5, 2018. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will discuss the Company’s business and development programs in an analyst-led fireside chat, and importantly, will review recent progress of the Company’s lung cancer strategy for ZEJULA and its immuno-oncology programs. The fireside chat will be webcast on September 5 from 12:15 to 1:15 PM ET, and TESARO will also host meetings with investors.
- The Baird 2018 Global Healthcare Conference at the InterContinental New York Barclay in New York City on Wednesday, September 5. Tim Pearson, Executive Vice President and CFO of TESARO, and Grant Bogle, Senior Vice President and Chief Commercial Officer of TESARO, are scheduled to participate in an analyst-led fireside chat from 12:15 to 12:45 PM ET on September 5, and will also host meetings with investors.
- The Wells Fargo Global Healthcare Conference at the Westin Copley Place in Boston on Thursday, September 6. Lonnie Moulder and Mary Lynne Hedley, Ph.D., are scheduled to present an overview of the Company’s business and development programs at 11:30 AM ET on September 6, and will also host meetings with investors.
Live webcasts of the presentations at the Citi, Baird, and Wells Fargo conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: